keyword
MENU ▼
Read by QxMD icon Read
search

Gynecologic oncology group

keyword
https://www.readbyqxmd.com/read/28410284/european-surgical-education-and-training-in-gynecologic-oncology-the-impact-of-an-accredited-fellowship
#1
Luis M Chiva, Jose Mínguez, Denis Querleu, David Cibula, Andreas du Bois
OBJECTIVE: The aim of this study was to understand the current situation of surgical education and training in Europe among members of the European Society of Gynecological Oncology (ESGO) and its impact on the daily surgical practice of those that have completed an accredited fellowship in gynecologic oncology. METHODS: A questionnaire addressing topics of interest in surgical training was designed and sent to ESGO members with surgical experience in gynecologic oncology...
April 13, 2017: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/28399033/european-society-of-gynaecological-oncology-guidelines-for-the-management-of-patients-with-vulvar-cancer
#2
Maaike H M Oonk, François Planchamp, Peter Baldwin, Mariusz Bidzinski, Mats Brännström, Fabio Landoni, Sven Mahner, Umesh Mahantshetty, Mansoor Mirza, Cordula Petersen, Denis Querleu, Sigrid Regauer, Lukas Rob, Roman Rouzier, Elena Ulrikh, Jacobus van der Velden, Ignace Vergote, Linn Woelber, Ate G J van der Zee
OBJECTIVE: The aim of this study was to develop clinically relevant and evidence-based guidelines as part of European Society of Gynaecological Oncology's mission to improve the quality of care for women with gynecologic cancers across Europe. METHODS: The European Society of Gynaecological Oncology Council nominated an international development group made of practicing clinicians who provide care to patients with vulvar cancer and have demonstrated leadership and interest in the management of patients with vulvar cancer (18 experts across Europe)...
April 8, 2017: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/28399028/pathologic-and-treatment-outcomes-among-a-geriatric-population-of-endometrial-cancer-patients-an-nrg-oncology-gynecologic-oncology-group-ancillary-data-analysis-of-lap2
#3
Erin A Bishop, James J Java, Kathleen N Moore, Joan L Walker
OBJECTIVES: Elderly endometrial cancer patients have worse disease-specific survival than their younger counterparts, but the cause for this discrepancy is unknown. The goal of this analysis is to compare outcomes by age in a fully staged elderly endometrial cancer population. METHODS/MATERIALS: This is an analysis of patients on Gynecologic Oncology Group Study (GOG) LAP2, which included clinically early stage endometrial cancer patients randomized to laparotomy versus laparoscopy for surgical staging...
April 8, 2017: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/28398847/traceback-a-proposed-framework-to-increase-identification-and-genetic-counseling-of-brca1-and-brca2-mutation-carriers-through-family-based-outreach
#4
Goli Samimi, Marcus Q Bernardini, Lawrence C Brody, Charlisse F Caga-Anan, Ian G Campbell, Georgia Chenevix-Trench, Fergus J Couch, Michael Dean, Joanne A de Hullu, Susan M Domchek, Ronny Drapkin, Heather Spencer Feigelson, Michael Friedlander, Mia M Gaudet, Marline G Harmsen, Karen Hurley, Paul A James, Janice S Kwon, Felicitas Lacbawan, Stephanie Lheureux, Phuong L Mai, Leah E Mechanic, Lori M Minasian, Evan R Myers, Mark E Robson, Susan J Ramus, Lisa F Rezende, Patricia A Shaw, Thomas P Slavin, Elizabeth M Swisher, Masataka Takenaka, David D Bowtell, Mark E Sherman
In May 2016, the Division of Cancer Prevention and the Division of Cancer Control and Population Sciences, National Cancer Institute, convened a workshop to discuss a conceptual framework for identifying and genetically testing previously diagnosed but unreferred patients with ovarian cancer and other unrecognized BRCA1 or BRCA2 mutation carriers to improve the detection of families at risk for breast or ovarian cancer. The concept, designated Traceback, was prompted by the recognition that although BRCA1 and BRCA2 mutations are frequent in women with ovarian cancer, many such women have not been tested, especially if their diagnosis predated changes in testing guidelines...
April 11, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28398498/prognostic-factors-for-patients-with-brain-metastasis-from-gynecological-cancer-a-significance-of-treatment-free-interval-of-more-than-6-months
#5
Sho Takeshita, Yukiharu Todo, Yu Furuta, Kazuhira Okamoto, Shinichiro Minobe, Katsushige Yamashiro, Hidenori Kato
Objective: Treatment-free interval has been confirmed as a significant prognostic factor in recurrent gynecological cancers. However, treatment-free interval has not been evaluated in previous studies investigating brain metastasis from gynecological malignancies. The aim of the study was to establish a predictive model of survival period after brain metastasis from gynecological cancer. Methods: Of a total of 2848 patients with gynecological cancer, patients with brain metastasis were included in the study...
April 7, 2017: Japanese Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28392124/surgical-pathological-findings-in-type-1-and-2-endometrial-cancer-an-nrg-oncology-gynecologic-oncology-group-study-on-gog-210-protocol
#6
William T Creasman, Shamshad Ali, David G Mutch, Richard J Zaino, Matthew A Powell, Robert S Mannel, Floor J Backes, Paul A DiSilvestro, Peter A Argenta, Michael L Pearl, Shashikant B Lele, Saketh R Guntupalli, Steven Waggoner, Nick Spirtos, John F Boggess, Robert P Edwards, Virginia L Filiaci, David S Miller
OBJECTIVE: To report clinical and pathologic relationships with disease spread in endometrial cancer patients. METHODS: Surgical candidates with uterine cancer (adenocarcinoma or carcinosarcoma) who were eligible to participate in a surgical pathological study to create a clinically annotated tissue biorepository to support translational and clinical research studies. All patients were to undergo a hysterectomy, bilateral salpingo-oophorectomy, and bilateral pelvic and para-aortic lymphadenectomy...
April 6, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28376204/nonsteroidal-anti-inflammatory-drugs-and-endometrial-carcinoma-mortality-and-recurrence
#7
Theodore M Brasky, Ashley S Felix, David E Cohn, D Scott McMeekin, David G Mutch, William T Creasman, Premal H Thaker, Joan L Walker, Richard G Moore, Shashikant B Lele, Saketh R Guntupalli, Levi S Downs, Christa I Nagel, John F Boggess, Michael L Pearl, Olga B Ioffe, Kay J Park, Shamshad Ali, Louise A Brinton
Background: Recent data suggest that the use of nonsteroidal anti-inflammatory drugs (NSAIDs) may be associated with reductions in endometrial cancer risk, yet very few have examined whether their use is related to prognosis among endometrial cancer patients. Methods: Study subjects comprised 4374 participants of the NRG Oncology/Gynecology Oncology Group 210 Study with endometrial carcinoma who completed a presurgical questionnaire that assessed history of regular prediagnostic NSAID use and endometrial cancer risk factors...
March 1, 2017: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/28358708/improvement-of-perioperative-outcomes-in-major-gynecological-and-gynecologic-oncological-surgery-with-hemostatic-gelatin-thrombin-matrix
#8
Rafał Watrowski, Christoph Jäger, Johannes Forster
AIM: To assess the impact of the use of intraoperative hemostatic gelatin-thrombin matrix (HM) (Floseal®, Baxter Healthcare) on transfusion rates and short-term perioperative outcomes in gynecological surgery. PATIENTS AND METHODS: In this retrospective, single-center study, we evaluated data of 215 patients (83 cases and 132 controls) undergoing extensive gynecological surgery (e.g. oncological procedures) with and without intraoperative HM application. RESULTS: Cases and controls did not differ according to age, preoperative hemoglobin (Hb) concentration, and Hb or C-reactive protein (CRP) levels at discharge...
March 2017: In Vivo
https://www.readbyqxmd.com/read/28355688/-a-randomized-study-of-intensity-modulated-radiation-therapy-versus-three-dimensional-conformal-radiation-therapy-for-pelvic-radiation-in-patients-of-post-operative-treatment-with-gynecologic-malignant-tumor
#9
J Ni, Z M Yin, S H Yuan, N F Liu, L Li, X X Xu, H M Lou
Objective: To study the difference between intensity-modulated radiation therapy (IMRT) and three dimensional conformal radiation therapy (3D-CRT) for pelvic radiation of post-operative treatment with gynecologic malignant tumor. Methods: A prospective investigation study was conducted on 183 patients of post-operative patients with whole pelvic radiation therapy of cervical cancer or endometrial cancer in Zhejiang Cancer Hospital [IMRT group (n=85) and 3D-CRT group (n=98)] from Oct. 2015 to Oct. 2016. The two groups received same dose (45 Gy in 25 fractions)...
March 25, 2017: Zhonghua Fu Chan Ke za Zhi
https://www.readbyqxmd.com/read/28341300/a-phase-i-pharmacokinetic-study-of-intraperitoneal-bortezomib-and-carboplatin-in-patients-with-persistent-or-recurrent-ovarian-cancer-an-nrg-oncology-gynecologic-oncology-group-study
#10
Danielle A Jandial, William E Brady, Stephen B Howell, Heather A Lankes, Russell J Schilder, Jan H Beumer, Susan M Christner, Sandra Strychor, Matthew A Powell, Andrea R Hagemann, Kathleen N Moore, Joan L Walker, Paul A DiSilvestro, Linda R Duska, Paula M Fracasso, Don S Dizon
PURPOSE: Intraperitoneal (IP) therapy improves survival compared to intravenous (IV) treatment for women with newly diagnosed, optimally cytoreduced, ovarian cancer. However, the role of IP therapy in recurrent disease is unknown. Preclinical data demonstrated IP administration of the proteasome inhibitor, bortezomib prior to IP carboplatin increased tumor platinum accumulation resulting in synergistic cytotoxicity. We conducted this phase I trial of IP bortezomib and carboplatin in women with recurrent disease...
May 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28338493/surgery-for-recurrent-uterine-cancer-surgical-outcomes-and-implications-for-survival-a-case-series
#11
Lavinia Domenici, Katherine Nixon, Flavia Sorbi, Maria Kyrgiou, Joseph Yazbek, Marcia Hall, Jeremy Campbell, Norma Gibbons, Won-Ho Edward Park, Hani Gabra, Christina Fotopoulou
OBJECTIVE: The purpose of this study was to describe the patterns of relapse in uterine cancer (UC) and the role of surgery in the recurrent setting. METHODS: We describe surgical and clinical outcomes of all patients who underwent surgery for recurrent UC in a gynecological oncology tertiary referral center between May 1, 2013, and April 30, 2016. Progression-free survival and overall survival were estimated using Kaplan-Meier methods with the surgery at relapse being the starting point...
March 23, 2017: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/28334914/clinical-utility-of-a-self-administered-questionnaire-for-assessment-of-hereditary-gynecologic-cancer
#12
Kenta Masuda, Akira Hirasawa, Haruko Irie-Kunitomi, Tomoko Akahane, Arisa Ueki, Yusuke Kobayashi, Wataru Yamagami, Hiroyuki Nomura, Fumio Kataoka, Eiichiro Tominaga, Kouji Banno, Nobuyuki Susumu, Daisuke Aoki
Background: A patient's medical history and familial cancer history are important information for assessing the risk of hereditary cancer. We have generated a self-administered questionnaire for patients with gynecologic cancer. This pilot study analyzed the usefulness of this questionnaire and the rates of patients that meet the Society of Gynecologic Oncology criteria in ovarian cancer and endometrial cancer patients. Method: Ovarian or endometrial cancer patients were recruited for this study...
December 23, 2017: Japanese Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28327944/a-phase-2-randomized-double-blind-placebo-%C3%A2-controlled-study-of-chemo-immunotherapy-combination-using-motolimod-with-pegylated-liposomal-doxorubicin-in-recurrent-or-persistent-ovarian-cancer-a-gynecologic-oncology-group-partners-study
#13
B J Monk, M F Brady, C Aghajanian, H A Lankes, T Rizack, J Leach, J M Fowler, R Higgins, P Hanjani, M Morgan, R Edwards, W Bradley, T Kolevska, P Foukas, E Swisher, K S Anderson, R Gottardo, J K Bryan, M Newkirk, K L Manjarrez, R S Mannel, R M Hershberg, G Coukos
Background: A phase 2, randomized, placebo-controlled trial was conducted in women with recurrent epithelial ovarian carcinoma to evaluate the efficacy and safety of motolimod-a Toll-like receptor 8 (TLR8) agonist that stimulates robust innate immune responses-combined with pegylated liposomal doxorubicin (PLD), a chemotherapeutic that induces immunogenic cell death. Patients and methods: Women with ovarian, fallopian tube, or primary peritoneal carcinoma were randomized 1 : 1 to receive PLD in combination with blinded motolimod or placebo...
February 21, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28324920/an-open-label-randomized-parallel-phase-ii-trial-to-evaluate-the-efficacy-and-safety-of-a-cremophor-free-polymeric-micelle-formulation-of-paclitaxel-as-first-line-treatment-for-ovarian-cancer-a-korean-gynecologic-oncology-group-study-kgog-3021
#14
Shin-Wha Lee, Yong-Man Kim, Chi Heum Cho, Young Tae Kim, Seok Mo Kim, Soo Young Hur, Jae-Hoon Kim, Byoung-Gie Kim, Seung-Cheol Kim, Hee-Sug Ryu, Soon Beom Kang
Purpose: Genexol-PM is a biodegradable cremophor EL-free polymeric micelle formulation of paclitaxel. Here we compared efficacy and safety of Genexol-PM plus carboplatin vs. Genexol plus carboplatin for ovarian cancer treatment. Materials and Methods: In this multicenter, randomized, phase II study, patients with FIGO IC-IV epithelial ovarian cancer were randomly assigned (1:1) to receive Genexol-PM 260 mg/m2 or Genexol 175 mg/m2 with 5 AUC carboplatin every three weeks (6 cycles)...
March 21, 2017: Cancer Research and Treatment: Official Journal of Korean Cancer Association
https://www.readbyqxmd.com/read/28314589/fgfr2-mutations-are-associated-with-poor-outcomes-in-endometrioid-endometrial-cancer-an-nrg-oncology-gynecologic-oncology-group-study
#15
Yvette W Jeske, Shamshad Ali, Sara A Byron, Feng Gao, Robert S Mannel, Rahel G Ghebre, Paul A DiSilvestro, Shashikant B Lele, Michael L Pearl, Amy P Schmidt, Heather A Lankes, Nilsa C Ramirez, Golnar Rasty, Matthew Powell, Paul J Goodfellow, Pamela M Pollock
PURPOSE: Activating FGFR2 mutations have been identified in ~10% of endometrioid endometrial cancers (ECs). We have previously reported that mutations in FGFR2 are associated with shorter disease free survival (DFS) in stage I/II EC patients. Here we sought to validate the prognostic importance of FGFR2 mutations in a large, multi-institutional patient cohort. METHODS: Tumors were collected as part of the GOG 210 clinical trial "Molecular Staging of Endometrial Cancer" where samples underwent rigorous pathological review and had more than three years of detailed clinical follow-up...
March 14, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28303492/contributions-of-the-japanese-gynecologic-oncology-group-jgog-in-improving-the-quality-of-life-in-women-with-gynecological-malignancies
#16
REVIEW
Masayuki Futagami, Yoshihito Yokoyama, Muneaki Shimada, Shinya Sato, Etsuko Miyagi, Akiko Tozawa-Ono, Nao Suzuki, Masaki Fujimura, Yoichi Aoki, Satoru Sagae, Toru Sugiyama
The Japanese Gynecologic Oncology Group (JGOG) is leading Japan in the treatment of gynecological malignancies. The JGOG consists of three treatment committees focusing on uterine cervical cancer, endometrial cancer, and ovarian cancer. Each committee makes efforts to improve treatment and diagnosis. In addition, the Supportive and Palliative Care Committee was established in 2015. Novel studies of supportive care and palliative care have been initiated by this committee. Furthermore, surveys about not only treatment results such as overall survival rates but also quality of life (QOL) and cost-effectiveness assessments are performed by the ovarian cancer committee...
April 2017: Current Oncology Reports
https://www.readbyqxmd.com/read/28293723/continuous-wound-infiltration-system-for-postoperative-pain-management-in-gynecologic-oncology-patients
#17
Banghyun Lee, Kidong Kim, Soyeon Ahn, Hyun-Jung Shin, Dong Hoon Suh, Jae Hong No, Yong Beom Kim
PURPOSE: Major open surgery for gynecologic cancer usually involves a long midline skin incision and induces severe postoperative surgical site pain (POSP) that may not be effectively controlled with the conventional management. We investigated whether combining a continuous wound infiltration system (CWIS, ON-Q PainBuster(®)) and intravenous patient-controlled analgesia (IV PCA) effectively decreases POSP, compared with IV PCA alone, in gynecologic oncology patients. METHODS: This retrospective study included 62 Korean patients who received a long midline skin incision during gynecologic cancer surgery...
March 14, 2017: Archives of Gynecology and Obstetrics
https://www.readbyqxmd.com/read/28285845/a-stratified-randomized-double-blind-phase-ii-trial-of-celecoxib-for-treating-patients-with-cervical-intraepithelial-neoplasia-the-potential-predictive-value-of-vegf-serum-levels-an-nrg-oncology-gynecologic-oncology-group-study
#18
Janet S Rader, Michael W Sill, Jan H Beumer, Heather A Lankes, Doris Mangiaracina Benbrook, Francisco Garcia, Connie Trimble, J Tate Thigpen, Richard Lieberman, Rosemary E Zuna, Charles A Leath, Nick M Spirtos, John Byron, Premal H Thaker, Shashikant Lele, David Alberts
PURPOSE: To examine the effect of celecoxib on cervical intraepithelial neoplasia 3 (CIN 3). This is a NRG Oncology/Gynecologic Oncology Group study with translational biomarkers. PATIENTS AND METHODS: Patients with CIN 3 were randomized to celecoxib 400mg once daily (67 patients) or placebo (63 patients) for 14-18weeks. The primary outcome measure was histologic regression. A test of equal probabilities of success between two therapies was conducted, using Fisher's Exact Test at alpha=10% and 90% power when the treatment arm boosted the probability of success by 30%...
March 9, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28285537/milestone-clinical-trials-of-the-national-surgical-adjuvant-breast-and-bowel-project-nsabp
#19
REVIEW
Priya Rastogi, D Lawrence Wickerham, Charles E Geyer, Eleftherios P Mamounas, Thomas B Julian, Norman Wolmark
The National Surgical Adjuvant Breast and Bowel Project (NSABP) has made significant contributions in reducing the extent of breast surgery and in improving outcomes of patients with early-stage breast cancer through the conduct of large randomized clinical trials evaluating local and systemic therapy. In 2014, the NSABP merged with two other US National Cancer Institute-funded cooperative groups, the Radiation Therapy Oncology Group (RTOG) and the Gynecologic Oncology Group (GOG), to form NRG Oncology. The combined organization has 218 member institutions with more than 600 affiliate centers located throughout the United States, Canada, Puerto Rico, and other international sites...
February 2017: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/28196674/cost-effectiveness-analysis-of-dose-dense-versus-standard-intravenous-chemotherapy-for-ovarian-cancer-an-economic-analysis-of-results-from-the-gynecologic-oncology-group-protocol-262-randomized-controlled-trial
#20
Brandon-Luke L Seagle, Shohreh Shahabi
OBJECTIVES: To determine the cost-effectiveness of dose-dense versus standard intravenous adjuvant chemotherapy for ovarian cancer using results from the no-bevacizumab cohort of the Gynecologic Oncology Group protocol 262 (GOG-262) randomized controlled trial, which reported a smaller absolute progression-free survival (PFS) benefit than the prior Japanese trial. METHODS: A three-state Markov decision model from a healthcare system perspective with a 21day cycle length and 28month time-horizon was used to calculate incremental cost-effectiveness ratio (ICER) values per progression-free life-year saved (PFLYS) using results from GOG-262...
February 10, 2017: Gynecologic Oncology
keyword
keyword
59468
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"